[1] KANEDA H，TAGUCHI J，OGASAWARA K，et al. Increased level of advanced oxidation protein products in patients with coronary artery disease[J] . Atherosclerosis，2002，162(1)：221-225. [2] FRYE E B，DEGENHARDT T P，THORPE S R，et al. Role of the maillard reaction in aging of tissue proteins. Advanced glycosylation end product-dependant increase in imidazolium cross-links in human lens proteins[J] . J Biol Chem，1998，273(30)：18714-18719. [3] NICHOLL I D，BUCALA R. Advanced glycation end products and cigarette smoking[J] . Cell Mol Biol，1998，44(7)：1025-1033. [4] ZHENG F，CAI W，MITSUHASHI T，et al. Lysozyme enhances renal excretion of advanced glycation end products in vivo and suppresses adverse age-mediated cellular effects in vitro：a potential AGE sequestration therapy for diabetic nephropathy[J] .Mol Med，2001，7(11)：737-747. [5] THORNALLEY P J，LANGBORG A，MINHAS H S. Formation of glyoxal，methyglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose[J] . Biochem J，1999，344(Pt1)：109-116. [6] SUZUKI H，KURIHARA Y，TAKEYA M，et al. A role for mecrophage scavenger receptors in atherosclerosis and susceptibility to infection[J] . Nature，1997，386(6622)：292-296. [7] STITT A W，BURKE G A，CHEN F，et al. Advanced glycation endproduct receptor interactions on microvascular cells occur within caeolin-rich membrane domains[J] .FASEB J，2000，14：2390-2392. [8] BUCCIARELLI L G，WENDT T，RONG L，et al. RAGE is a multiligand receptor of the immunoglobulin superfamily：implications for homeostasis and chronic disease[J] . Cell Mol Life Sci，2002，59(7)：1117-1128. [9] AHMED N. Advanced glycation endproducts--role in pathology of diabetic complications[J] .Diabetes Res Clin Pract，2005，67(1)：3-21. [10] SCHMIDT A M, YAN S D, YAN S F ，et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses[J] . J Clin Invest，2001，108：949-955. [11] HUDSON B I，SCHMIDT A M. RAGE：a novel target for drug intervention in diabetic vascular disease[J] . Pharm Res，2004，21(7)：1079-1086. [12] BUCALA R，LEE A T，ROURKE L，et al. Transposition of an Alu-containing element induced by DNA-advanced glycosylation endproducts[J] . Proc Natl Acad Sci，1993，90(7)：2666-2670. [13] JANDELEIT-DAHM K A, LASSILA M，ALLEN T J.Advanced glycation end products in diabetes-associated atherosclerosis and renal disease：interventional studies[J] . Ann N Y Acad Sci，2005，1043：759-766. [14] JONO T，MIYAZAKI A，NAGAI R，et al. Lectin-like oxidized low density lipoprotein receptor-1 (LOX-1) serves as an endothelial receptor for advanced glycation end products (AGE)[J] . FEBS Lett，2002，511(1-3)：170-174. [15] JINNOUCHI Y，SANO H，NAGAI R，et al. Glycolaldehyde-modified low density lipoprotein leads macrophages to foam cells via the macrophage scavenger receptor[J] . J Biochem(Tokyo)，1998，123(6)：1208-1217. [16] CIPOLLONE F，IEZZI A，FAZIA M，et al. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques：role of glycemic control[J] . Circulation，2003，108(9)：1070-1077. [17] ZIEMAN S，KASS D. Advanced glycation end product cross-linking：pathophysiologic role and therapeutic target in cardiovascular disease[J] .Congest Heart Fail，2004，10(3)：144-149. [18] BASTA G，SCHMIDT A M，DE CATERUNA R. Advanced glycation end products and vascular inflammation：implications for accelerated atherosclerosis in diabetes[J] .Cardiovasc Res，2004，63(4)：582-592. [19] KATO S，HORIUCHI S，LIU J，et al. Advanced glycation endproduct-modified superoxide dismutase-1 (SOD1)-positive inclusions are common to familial amyotrophic lateral sclerosis patients with SOD1 gene mutations and transgenic mice expressing human SOD1 with a G85R mutation[J] . Acta Neuropathol (Berl)，2000，100(5)：490-505. [20] ZORC M，ZORC-PLESKOVIC R，VRASPIR-PORENTA O，et al. Apoptosis and histopathologic changes in diffuse coronary atherosclerosis[J] . Angiology，2003，54(1)：81-84. [21] BEAUCHAMP M C, MICHAUD S E, LI L，et al. Advanced glycation end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression[J] . J Lipid Res，2004，45(9)：1749-1757. [22] OHGAMI N，MIYAZAKI A，SAKAI M，et al. Advanced glycation end products (AGE) inhibit scavenger receptor class B type I-mediated reverse cholesterol transport：a new crossroad of AGE to cholesterol metabolism[J] . J Atheroscler Thromb，2003，10(1)：1-6. [23] VEIRAIAH A. Hyperglycemia，lipoprotein glycation，and vascular disease[J] .Angiology，2005，56(4)：431-438. [24] VASAN S，FOILES P，FOUNDS H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks[J] . Arch Biochem Biophys，2003，419：89-96. [25] CANDIDO R，FORBES J M，THOMAS M C，et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes[J] .Circ Res，2003，92：785-792. [26] KASS D A，SHAPIRO E P，KAWAGUCHI M，et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker[J] . Circulation，2001，104：1464-1470. [27] MIYATA T，VAN YPERSELE DE STRIHOU C，UEDA Y，et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products：biochemical mechanisms[J] . J Am Soc Nephrol，2002，13：2478-2487. [28] FORBRS J M，COOPER M E，THALLAS V，et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy[J] . Diabetes，2002，51：3274-3282.